Trials / Not Yet Recruiting
Not Yet RecruitingNCT07533942
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JZP3507 | Participants will receive oral JZP3507 monotherapy twice daily, on 3 consecutive days per week in 28-day cycles. |
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2028-10-25
- Completion
- 2031-10-16
- First posted
- 2026-04-16
- Last updated
- 2026-04-16
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07533942. Inclusion in this directory is not an endorsement.